Floatz logo

Osimertinib

MET Gene Mutation

Hunan Province Tumor HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the MET Gene Mutation cohort.

Asset / SponsorPhaseRating
Crizotinib
Hunan Province Tumor Hospital
Phase 2CCC
VOLITINIB
Hunan Province Tumor Hospital
Phase 2CCC
ALECTINIB
Hunan Province Tumor Hospital
Phase 2CCC
sym015
Symphogen A/S
Phase 1/2CCC
Capmatinib
Asan Medical Center
Phase 2CCC
egf816
Asan Medical Center
Phase 2CC

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →